Kangli Bio

Kangli was founded in 1993, headquartered in Shenzhen, China, with its production base located in Meizhou, Guangdong. After three decades of continuous development and growth, it has grown into a national high-tech enterprise with more than 400 employees specializing in the research and development, production, and sales of "in vitro diagnostic instruments and reagents," among whom R&D personnel with bachelor's, master's, and doctoral degrees account for 30%. Leveraging the comprehensive environmental advantages of the Shenzhen Special Economic Zone, the Shenzhen base is mainly responsible for technology research and development, product innovation, and market development, with an R&D center covering an area of more than 3,000 square meters. At the same time, the Kangli High-tech Industrial Park has been built in Meizhou, covering an area of 40 mu, with approximately 20,000 square meters of production plants completed in the * phase, becoming a new window for the local medical industry. Kangli also has a high-standard reagent production workshop of more than 2,000 square meters. At present, Kangli's annual production scale can reach 20,000 units. It is not only a large electrolyte analyzer manufacturer in China, but also a leading expert in the field of blood gas and electrolytes at home and abroad, having always focused on research and development and innovation in the fields of electrolyte analysis and blood gas analysis, and possessing core technologies and complete intellectual property rights of its products. In 2006, Kangli launched its independently developed blood gas electrolyte analyzer, filling the gap in the domestic in vitro diagnostic field and breaking the long-term situation of monopoly and technological blockade by foreign manufacturers in this field, becoming a * in China's blood gas field. In 2021, Kangli's blood gas analyzer was listed among outstanding domestic medical devices, and in the same year it became a domestic * enterprise participating in the formulation of blood gas industry standards, possessing the strength to compete with major international companies and leading the new era of national blood gas! Kangli upholds the quality policy of "first-class products, satisfactory service, continuous improvement," strictly follows the requirements of ISO9001 and ISO13485 quality system certification, ensures excellent product quality and experience, and provides high-quality products, solutions, and efficient and valuable professional services that meet clinical needs. Kangli fully leverages regional, industry, and national environmental support and favorable policies to continuously enhance its comprehensive competitiveness and vigorously expand its market territory. It not only occupies a pivotal position in the domestic market, with users covering all provinces across the country and more than 10,000 users nationwide; it has also achieved gratifying results in the international market, with products exported to nearly 100 countries around the world. Kangli adheres to valuable innovation, is committed to becoming a * supplier of in vitro diagnostic products, and contributing to the cause of human health. With "focus, innovation, and joy" as its core corporate culture, it creates a good office environment and continuously invests in cultivating top-tier scientific and medical industry personnel. Carrying forward the spirit of craftsmanship, it is ready to meet challenges and, in the future, takes building national blood gas as its mission and strives for the rise of national blood gas.